Erasca at an Inflection - Hold Through ERAS-0015 Readouts, Trim on Weakness

Hook & thesis

Erasca has one of the clearest single-drug stories in small-cap oncology right now: ERAS-0015, a pan-RAS molecular glue, has shown early safety and responses in Phase 1 and now benefits from a clinical trial collaboration with Merck announced on 05/11/2026. That partnership validates the science and opens a straightforward combo path with pembrolizumab that could materially de-risk the program if the data hold.

At the same time, Erasca is fighting fire on two fronts: a patent infringement and trade-secret allegation from Revolution Medicines disclosed on 04/28/2026 that triggered a steep selloff, and an active securities investigation highlighted by class-action counsel. Those are not small hurdles; they increase headline volatility and the chance of settlement costs or injunctions. For that reason our stance is Hold - we favor staying the course if you already own shares, but we recommend prudently sized positions with a clear stop. New buyers should wait for either clearer clinical readouts or meaningful legal resolution.

What Erasca does and why the market should care

Erasca is a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. Its flagship program, ERAS-0015, is a modality-agnostic pan-RAS molecular glue designed to target mutant RAS proteins that historically have been difficult to drug. The company has framed ERAS-0015 as a potential backbone for RAS-mutant solid tumor therapy, and early Phase 1 AURORAS-1 data reportedly showed favorable safety, tolerability, and clinical responses at low doses.

Why the market cares: RAS mutations are among the most common oncogenic drivers across solid tumors. A well-tolerated, broadly active anti-RAS agent that can be combined with checkpoint inhibitors like pembrolizumab could open very large addressable markets and attract partnership interest from Big Pharma. That dynamic is why Merck agreed to supply pembrolizumab free of charge for combo proof-of-concept testing in a collaboration announced on 05/11/2026.

Hard numbers that matter

Two valuation benchmarks stand out. First, Erasca traded as high as $24.28 in the last year; that tells you the market has previously priced in much of the upside should ERAS-0015 hit aggressive development milestones. Second, the company now has a market cap of about $3.25B despite negative earnings and negative free cash flow, reflecting investor willingness to value clinical-stage biotech on potential commercial outcomes rather than current profit metrics.

Technicals and market landscape

Momentum indicators are mixed-to-bearish: the 10-day SMA is around $10.17 while the 50-day SMA is near $15.33 and the 10/50-day EMAs show a downward tilt. The RSI at ~36.5 is on the low side, indicating the name is not overbought and may be structurally oversold given the legal headlines. Short interest is active: the latest settlement shows ~32.06M shares short (04/30/2026) with days-to-cover materially compressed in recent reporting periods. Recent short-volume readings show heavy shorting activity across several trading sessions, which adds to headline-driven volatility.

Catalysts to watch

• Phase 1 AURORAS-1 data updates for ERAS-0015 monotherapy and pembrolizumab combo - these could be incremental de-riskers if responses and tolerability are durable.
• Any public progress or legal filings related to the Revolution Medicines patent infringement and trade-secret allegations (original disclosure 04/28/2026) - settlement or a clear defense could remove a major overhang.
• Further partnership/biotech collaborations beyond the Merck combination announced 05/11/2026 - signals of commercial interest would re-rate sentiment.
• Clinical presentation dates or investigator updates at scientific conferences - these frequently move early-stage biotech valuations.

Trade plan - action for holders and traders

We recommend a Hold posture with explicit rules:

• Entry (for new traders wanting a contrarian, risk-controlled position): enter at $10.50 if you want exposure to ERAS-0015 clinical upside with tight risk controls.
• Stop-loss: $8.50 - a hard stop to protect capital in case the legal/clinical headlines worsen and push broader sell pressure. This allows approximately 19% downside risk from the $10.50 entry.
• Target: $15.00 - a reasonable mid-term target tied to the next tranche of clinical readouts or legal clarity. This reflects a re-rating toward the lower band of the prior 52-week trading range if positive clinical news arrives.
• Horizon: mid term (45 trading days) - we expect the most meaningful movement will cluster around upcoming trial announcements or legal milestones within the next one to two months. If the trade remains intact after positive readouts, consider extending to long term (180 trading days) to capture downstream value.

Practical notes: position size should be limited to a small percentage of portfolio risk budget given binary clinical and legal outcomes. For current holders, do not average up aggressively into the legal uncertainty; consider trimming a small portion to lock in capital and set a stop at $8.50 on the remainder.

Risks - the hard realities to price in

• Patent litigation and trade-secret allegations: Revolution Medicines' letter and related disclosures from 04/28/2026 are the largest near-term headline risk. An adverse judgment or injunction could materially impair ERAS-0015’s development or marketability.
• Securities litigation and reputational impact: The Schall Law Firm's investigation and any class-action activity could drive legal costs, management distraction, and further stock volatility.
• Clinical development risk: Early Phase 1 signals do not guarantee later-stage efficacy or safety. A negative data update or unexpected toxicity in combination studies would likely cause a deep selloff.
• Dilution and cash burn: Recent financing (closed 01/23/2026) raised gross proceeds near $258.8M, which extends runway but also means shareholder dilution has occurred. Continued negative free cash flow (recent figure -$95.6M) could prompt further funding needs if programs expand.
• Market and investor sentiment swings: Short interest and active short-volume trading amplify downside moves; a coordinated short thesis could accelerate price declines during weak periods.

Counterargument

There is a credible bull case. Merck's decision to supply pembrolizumab for combo testing on 05/11/2026 is a tangible vote of confidence: Big Pharma does not typically partner loosely on programs without meaningful scientific rationale. Additionally, early Phase 1 signals described publicly - favorable safety, tolerability, and low-dose responses - materially raise the probability that ERAS-0015 can be developed as a backbone therapy. Coupled with a cash runway the company parses as greater than three years, Erasca can press multiple clinical fronts before being forced to dilute again. If ERAS-0015 delivers convincing objective responses in a few tumor cohorts, valuation re-rating back toward prior highs is plausible.

Conclusion - what would change our view

Our current stance is Hold. For holders, the combination of positive scientific validation (Merck collaboration) and meaningful legal overhang argues for patience with defined risk controls. For new buyers we recommend waiting for either clinical data that materially reduces developmental binary risk or concrete legal progress that removes the patent overhang.

What would make us more constructive: a clear clinical dataset showing durable objective responses across multiple RAS-mutant cohorts, or a favorable resolution/clarification on the Revolution Medicines claim that eliminates the risk of an injunction. What would make us more bearish: any public court ruling or injunctive action that constrains ERAS-0015 development, or Phase 1/combination data showing unmanageable toxicity or lack of efficacy.

Key near-term watchlist

• Readouts or investigator updates from AURORAS-1 (ERAS-0015 monotherapy/combo) - primary catalyst for re-rating.
• Public legal filings or settlement announcements related to Revolution Medicines - could end or heighten the overhang.
• Any extension of the Merck collaboration or new commercial partnerships - would validate long-term optionality.

Trade summary: Hold if you own shares. New entries at $10.50 with a stop at $8.50 and a mid-term target of $15.00; limit position size and reassess after the next round of clinical and legal developments.